Christopher Maiona, MD
Hospitalist · Augusta, MENPI 1205881042
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 133 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 14.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,663 and has fallen 86.6% since, to $223 in 2025. Among hospitalist clinicians in ME with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 133 payments — averaging $21.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$409
- Novo Nordisk$339
- Lilly USA, LLC$328
- Novartis$290
- Pfizer$206
- Amgen$199
- plus $1K from 20 others
What the payments were for
- Food & beverage$2,828100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 19 | $409 |
| Novo Nordisk | 15 | $339 |
| Lilly USA, LLC | 15 | $328 |
| Novartis | 17 | $290 |
| Pfizer | 9 | $206 |
| Amgen | 10 | $199 |
| E.r. Squibb & Sons, L.L.C. | 4 | $129 |
| Johnson & Johnson | 5 | $118 |
| Exact Sciences | 5 | $109 |
| Merck | 4 | $88 |
| AstraZeneca | 4 | $75 |
| Abbott | 3 | $69 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $64 |
| Boehringer Ingelheim | 2 | $59 |
| Eisai Inc. | 2 | $58 |
| Shield Therapeutics Inc | 3 | $55 |
| Phathom Pharmaceuticals, Inc. | 2 | $44 |
| Sumitomo Pharma America, Inc. | 2 | $35 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Hologic Sales And Service, LLC | 1 | $23 |
| Mylan Specialty L.p. | 1 | $21 |
| Idorsia Pharmaceuticals US Inc | 1 | $21 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Dexcom, Inc. | 1 | $15 |
| Bayer | 1 | $15 |
How this compares
$2,828 in reported general payments places this provider in the 95th percentile of 171 hospitalist providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 67 | $38,048 |
| TrulicityDulaglutide | 24 | $30,244 |
| JardianceEmpagliflozin | 20 | $22,417 |
| OzempicSemaglutide | 11 | $13,890 |
| Atorvastatin Calcium | 249 | $2,932 |
| Midodrine Hcl | 13 | $1,253 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 34 | $1,249 |
| Amlodipine Besylate | 149 | $1,221 |
| Rosuvastatin Calcium | 39 | $1,186 |
| Mirtazapine | 46 | $1,074 |
| Metoprolol Succinate | 81 | $1,073 |
| Clozapine | 35 | $1,056 |
| Levothyroxine Sodium | 122 | $975 |
| Ezetimibe | 21 | $834 |
| Lisinopril | 112 | $750 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $206 | $38,04867 claims |
| Lilly USA, LLCTrulicity | $328 | $30,24424 claims |
| Boehringer IngelheimJardiance | $59 | $22,41720 claims |
| Novo NordiskOzempic | $339 | $13,89011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 171 hospitalist providers in Maine.
Other hospitalist in Augusta
- Reynerio LanoyAugusta$239
- Lauren NovitskieAugusta$32
- Claudia DiblasiAugusta$22
- Robert TavaresAugusta$15
- Carlos Requena ArmasBangor$8K
- Hans Reyes GarayBangor$6K
- Alexander KulczyckiBar Harbor$6K
- Daniel GoodmanPortland$907
- Bonnie PatrickBiddeford$771
- Linda GiffordRockport$629
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.